Cargando…
SAT404 Achieving Both Target Testosterone And Target Estradiol Levels May Not Be Practical In All Trans Feminine Users Of Estradiol - Which To Prioritize?
Disclosure: D. Slack: None. N. Krishnamurthy: None. F. Contreras-Castro: None. J.D. Safer: None. For feminizing gender affirming hormone therapy (GAHT), the Endocrine Society and WPATH SOC 8 suggest targeting testosterone (T) levels below 50 ng/dL and estradiol (E2) levels in the range of 100-200 pg...
Autores principales: | Slack, Daniel, Krishnamurthy, Nithya, Contreras-Castro, Felix, Safer, Joshua David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554830/ http://dx.doi.org/10.1210/jendso/bvad114.2075 |
Ejemplares similares
-
SAT391 Supratherapeutic Estrogen Levels in Transgender Women Likely From Sublingual Estradiol
por: Jalal, Erica, et al.
Publicado: (2023) -
SAT409 Sublingual Estradiol Only, Compared To Combined Oral Estradiol And Cyproterone Acetate,Offers No Apparent Advantage For Gender Affirming Hormone Therapy (GHAT), In Treatment Naïve Transwomen: Results Of A Prospective Pilot Study
por: Yaish, Iris, et al.
Publicado: (2023) -
SAT392 A Case Of Idiopathic Intracranial Hypertension in Gender Dysphoria: Is Testosterone The Culprit?
por: Saad-Omer, Suhail, et al.
Publicado: (2023) -
SAT421 Near Term Cardiometabolic Outcomes of Testosterone Therapy In Transgender Boys And Men
por: Dey, Justin, et al.
Publicado: (2023) -
SAT398 Pubertal Status And Trends In Gender Affirming Treatment Of Transgender And Gender Diverse Youth
por: Lin, Cathy, et al.
Publicado: (2023)